Service Agreement ("Agreement") in relation to Study of Semaglutide Plasma Concentration in Subjects in a Phase 2 Randomized, Double-Blind, Controlled Trial to Explore the Efficacy, Safety, and Optimal Dose of Oral Semaglutide Tablets in Patients with Parkinson's Disease ("Study") entered on September 05, 2025 ("Effective Date").